Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 2,400 | 49% |
| 2020 | 39 | 1,994 | 52% |
| 2021 | 43 | 2,171 | 56% |
| 2022 | 42 | 1,828 | 59% |
| 2023 | 44 | 1,934 | 62% |
| 2024 | 47 | 1,837 | 64% |
| 2025 from claims | – | 2,015 1,849–2,132 | 65% |
| 2026 forecast | – | 2,262 1,990–2,610 | 61% |
| 2027 forecast | – | 2,319 1,982–2,763 | 61% |
| 2028 forecast | – | 2,377 1,984–2,911 | 61% |
| 2029 forecast | – | 2,437 1,991–3,057 | 60% |
| 2030 forecast | – | 2,499 2,002–3,202 | 60% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 36% of the cases CMS names in Minnesota; 34 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 8% inpatient hospital, 87% hospital outpatient, 5% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 150 | 6,970−0.5%/yr | −0.5%/yr | 6.4 | 12% | 7,740 in 2030+1.8%/yr |
| Illinois | 148 | 6,158−2.8%/yr | −2.8%/yr | 4.5 | 13% | 6,630 in 2030+1.2%/yr |
| Indiana | 105 | 5,228−0.5%/yr | −0.5%/yr | 7.5 | 11% | 6,130 in 2030+2.7%/yr |
| Michigan | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.6 | 6% | 4,480 in 2030−0.8%/yr |
| Missouri | 83 | 3,766−2.6%/yr | −2.6%/yr | 6.1 | 19% | 4,330 in 2030+2.4%/yr |
| Wisconsin | 63 | 2,490−3.4%/yr | −3.4%/yr | 4.5 | 6% | 2,900 in 2030+2.6%/yr |
| Kansas | 44 | 2,107−0.8%/yr | −0.8%/yr | 5.2 | 20% | 2,660 in 2030+4%/yr |
| Iowa | 47 | 1,750−0.8%/yr | −0.8%/yr | 4.0 | 26% | 1,840 in 2030+0.9%/yr |
| Nebraska | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.8 | 12% | 1,880 in 2030+3.7%/yr |
| South Dakota | 18 | 618+1.8%/yr | +1.8%/yr | 4.8 | 0% | 810 in 2030+4.6%/yr |
| North Dakota | 10 | 352−6.2%/yr | −6.2%/yr | 3.6 | 0% | 360 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 25 | 1,559−8.7%/yr | −8.7%/yr | 3.40.7× | 14% | 1,980 in 2030+4.1%/yr |
| Hysterectomy, hysteroscopy & ablation | 18 | 1,547−1%/yr | −1%/yr | 3.81.3× | 9% | 2,280 in 2030+6.7%/yr |
| Incontinence, prolapse & sacral neuromodulation | 16 | 1,110+0.9%/yr | +0.9%/yr | 2.41.1× | 7% | 1,930 in 2030+9.7%/yr |
| Prostatectomy & nephrectomy | 10 | 773+1.1%/yr | +1.1%/yr | 1.91.4× | 0% | 1,410 in 2030+11%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Ohio
Calyxo leads with 55% of company spending on these surgeons in 2025, +26 pts on 2024.
In 2025, 3 companies reported engagement with Minnesota’s surgeons worth $17K in consulting, speaking, meals and travel tied to these products, about $356 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.